Merrimack Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.08.17	Merrimack Announces Date of One-for-Ten Reverse Stock Split (PR Newswire)
23.08.17	Stocks Under Scanner in the Biotech Space -- Merrimack Pharma, MannKind, NeuroDerm, and Celsion (PR Newswire)
14.08.17	Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer (PR Newswire)
09.08.17	Merrimack Reports Second Quarter 2017 Financial Results (PR Newswire)
02.08.17	Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call (PR Newswire)
24.07.17	Merrimack Appoints Thomas Needham as Chief Business Officer (PR Newswire)
28.06.17	Technical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and Radius Health (PR Newswire)
21.06.17	Key Pharma Stocks With Advanced Developments and Breakthrough Discoveries (PR Newswire)
21.06.17	Key Pharma Stocks With Advanced Developments and Breakthrough Discoveries (PR Newswire)
19.06.17	Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 (PR Newswire)
08.06.17	Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources (PR Newswire)
02.06.17	Gainers & Losers Of June 1: XBIT, CBMG, COLL, NEOT, MACK... (RTTNews)
01.06.17	Gainers & Losers Of May 31: NDRM, CBIO, SUPN, MACK, VSTM... (RTTNews)
25.05.17	Merrimack Announces Management Change (PR Newswire)
10.05.17	Merrimack Reports First Quarter 2017 Financial Results (PR Newswire)
02.05.17	Merrimack Announces Timing of First Quarter 2017 Investor Conference Call (PR Newswire)
17.04.17	Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research (PR Newswire)
06.04.17	Biotech Stocks on Investors' Radar -- Merrimack Pharma, Amicus Therapeutics, CEL-SCI, and Cempra (PR Newswire)
05.04.17	Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale (PR Newswire)
03.04.17	Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310 (PR Newswire)
30.03.17	Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion (PR Newswire)
27.03.17	Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting (PR Newswire)
23.03.17	Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors (PR Newswire)
01.03.17	Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results (PR Newswire)
22.02.17	Merrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call (PR Newswire)
06.02.17	Technical Reports on Biotech Stocks -- Amgen, Array BioPharma, Merrimack Pharma, and Alexion Pharma (PR Newswire)
20.01.17	Worthy Start of the Year for Biotech Companies (PR Newswire)
18.01.17	Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO (PR Newswire)
09.01.17	Merrimack Pulls Back Well Off Highs But Remains Positive (RTTNews)
09.01.17	Ipsen To Buy Merrimack's Oncology Assets, Including Onivyde (RTTNews)
09.01.17	EXAS Abuzz, MACK Makes Deal With Ipsen, XENE Awaits Data (RTTNews)
09.01.17	Ipsen To Acquire Oncology Assets From Merrimack Pharma - Quick Facts (RTTNews)
09.01.17	Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus (PR Newswire)
22.12.16	CALA Surges On BMY Deal, OVAS Hands Pink Slips, MACK Halts Breast Cancer Study (RTTNews)
21.12.16	Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer Patients (PR Newswire)
12.12.16	Biotech Stocks Under Review -- Mast Therapeutics, Array BioPharma, Opko Health, and Merrimack Pharma (PR Newswire)
04.10.16	DVAX Back In News, Spectral Shock For Investors, MACK Giving Pink Slips (RTTNews)
03.10.16	Merrimack Pharma Reduces Headcount By 22%; CEO Robert Mulroy Resigns (RTTNews)
25.07.16	Merrimack: ONIVYDE Regimen Gets Positive CHMP Opinion In EU -Quick Facts (RTTNews)
06.07.16	Merrimack: Seribantumab Gets Fast Track Designation In Patients With NSCLC (RTTNews)
23.10.15	FDA Snubs SPPI, OCUL Feels Pressure, It's Thumbs Up For MACK, But With Rider (RTTNews)
06.08.15	Merrimack Pharma Names Yasir Al-Wakeel CFO (RTTNews)
26.06.15	AQXP Fails To Lead, Concordia To Get Better Visibility, EXAC Gets FDA Nod (RTTNews)
25.06.15	Merrimack Pharma Says FDA Grants Priority Review For MM-398 NDA (RTTNews)
05.05.15	ACRX Deeply Pained, ISIS Cuts A Deal, AQXP Reaches Enrollment Target (RTTNews)
21.04.15	AMPE Severely Hurt, INGN Put On Notice, NYMX On The Rise, SGEN Gets FDA Date (RTTNews)
20.02.15	Mark Your Calendar For TCON, XLRN, Xenon Lights Up, MACK Gets Going (RTTNews)
20.11.14	CBMG To Keep On Your Radar, CEMP Gets Funding, MACK On Fast Track (RTTNews)
20.11.14	PharmaEngine, Merrimack's MM-398 Gets FDA Fast Track Designation (RTTNews)
19.11.14	Merrimack Pharma Gets Fast Track Designation For MM-398 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Zurich Insur Gr	582.00	3.23 %	K V
ABB	52.80	1.50 %	K V
CieFinRichemont	180.65	1.03 %	K V
Swiss Re	140.30	0.83 %	K V
Kuehne+Nagel Int	212.60	0.52 %	K V
Lonza Grp	576.20	-0.66 %	K V
Novartis	95.71	-0.91 %	K V
Alcon	80.06	-1.11 %	K V
Roche Hldg G	291.10	-1.22 %	K V
Sonova Hldg	293.70	-1.34 %	K V

Nachrichten zu Merrimack Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten